Bill Gates-Backed Surgical Robot Collapses, Chinese Rivals Cash In

Vicarious Surgical, a US surgical robotics company whose backers once included Bill Gates and medical device giant BD, has agreed to hand its assets to creditors and dissolve. The company, founded in 2014 by engineers with roots at Apple, spent twelve years chasing the operating table without ever getting there: no FDA clearance, no human clinical trial, and roughly $300 million raised along the way.

Its pitch was radical. Instead of a bulky console like the one that made Intuitive Surgical’s da Vinci system a hospital staple, Vicarious used a single-port approach paired with a VR headset, letting surgeons steer slim robotic arms into the body through one small incision. Investors saw a potential challenger to da Vinci, a franchise that has dominated soft-tissue robotic surgery for two decades. The technology looked like a leap; the regulatory and clinical path turned out to be a wall.

The contrast with China’s surgical robot sector is the part worth watching. While several American startups have struggled to convert prototypes into approved, revenue-generating products, a cluster of Chinese companies has been taking a slower, more commercial route: get devices through domestic regulatory review, sell into a large home market, and use that revenue to fund refinement. Some are now reporting that their surgical robot businesses have crossed into profit, or are close to it.

That difference is less about engineering brilliance than about sequencing. Chinese firms have generally targeted procedures where the clinical benefit is easy to demonstrate and hospitals are already buying, such as urology, gynecology and orthopedics. They have also leaned on domestic supply chains for components like precision arms, imaging and control systems, which shortens the distance between a design and a shippable unit.

Hospitals, meanwhile, are the real gatekeepers. A surgical robot only pays for itself if surgeons use it often enough, so vendors bundle training, maintenance and procedure support. In China, where top-tier hospitals handle enormous case volumes, that adoption loop can spin faster than in markets where each installation is a harder sell.

The cautionary tale from Vicarious is not that the technology was wrong. It is that a startup can burn a decade and hundreds of millions of dollars proving a concept while the market moves on. Regulators want clinical evidence; hospitals want reliability and service; payers want cost justification. A VR headset demo does not answer any of those questions.

For global readers, the takeaway is that the surgical robotics race is no longer a one-horse story. Da Vinci still sets the standard, and American and European innovators continue to push new designs. But the next wave of competition may come from companies that prioritized getting into operating rooms over getting into headlines — and that are now collecting the fees that come with it.